EGONE Prize

EGONE is the interactive e-learning portal that is used all over Switzerland for medical students, in the postgraduate as well as for continuing medical education. Behind the scenes, many colleagues are involved in EGONE: specialists, professors, the JFOR, pnn and, above all, specialist authors who check and revise the content of the scripts.  

To honour this great work and to motivate younger specialists to contribute, the first EGONE Prize has been awarded this year. Dr. med. Roger Rytz, president of the EGONE Fachrat and past president of gynécologie suisse SGGG gave the award to the authors of scriptO01B "Medications and pregnancy" during the social event of the annual congress of gynécologie suisse.  

EGONE Prize 2024

This year's EGONE Prize is awarded to the following authors team:

  • Prof Alice Panchaud, Primary Care Pharmacy at the Bern Institute of Family Medicine
  • Eva Gerbier, médecin assistante en gynécologie-obstétrique, CHUV
  • Andrea Burch, Vice President Swiss Academy of Perinatal Pharmacology, Head of Clinic Support, Swiss Academy of Perinatal Pharmacology; ZüriPharm AG

The jury was particularly impressed by the fact that the three prize winners delivered an excellent script that transcended both language barriers and the boundaries of the specialist disciplines.  
The EGONE Prize consists of an invitation to the social evening of the annual congress of gynécologie suisse, certificates and a sum of money. The prize of 2024 was financed by pnn ag, the operator of EGONE.

© www.haeslerfoto.ch Haesler Foto

­Script O01B "Medications and pregnancy"

For most drugs, there is insufficient data to quantify the teratogenic risk in humans. Hence, they cannot be considered safe for the embryo. However, given current drug approval conditions, it seems unlikely that approved medications lead to major teratogenic effects. Still, it is possible that minor teratogenic effects remain unidentified, particularly for rarely prescribed drugs. Altogether, there is no pregnancy specific recommendation for some common symptoms during pregnancy, such gastroesophageal reflux. Instead, recommendations for the general population can also be used during pregnancy given the relative safety of drugs used to treat this pathology. For other problems, such as lower urinary tract infection (cystitis), treatment during pregnancy follows specific recommendations. The EGONE Script O01B covers in detail the treatment recommendations for common diseases and symptoms during pregnancy and also provides an overview of all potentially teratogenic medicinal products. Furthermore, the script discusses recommended vaccinations and vaccinations to be avoided during pregnancy. In general, maternal vaccine-induced immunity (IgG) protects the fetus via transplacental transfer. To date, no vaccine has shown teratogenic effects on fetal development, but the extent of documented experience varies for each vaccine. Routine vaccinations should generally be carried out before pregnancy. Some vaccinations like influenza, COVID-19 and pertussis are recommended during pregnancy. Other vaccinations like measles, mumps, rubella (MMR) and Chickenpox should not be administered during the month preceding the pregnancy or during pregnancy due to a theoretical, but never observed, risk of embryopathy.
Overall, the script O01B "Medications and pregnancy" serves as a comprehensive, up-to-date source of information on the subject of medication during pregnancy.